Ingrezza (valbenazine) is a prescription drug that’s used to treat certain movement disorders. Ingrezza comes as a capsule that you swallow. Specifically, Ingrezza is used to treat these ...

This can affect how people see themselves and affect their social life. Ingrezza (in-GREH-zah) was approved in 2017 as the first medicine to help control movement in people with tardive ...

Ingrezza (valbenazine) is a prescription drug that’s used to treat tardive dyskinesia and chorea caused by Huntington’s disease. Ingrezza can cause mild to serious side effects. Examples ...

Ingrezza is a brand-name drug prescribed for tardive dyskinesia and chorea related to Huntington’s disease. Ingrezza has interactions with some other drugs and supplements, including ...

Ingrezza (valbenazine) comes hot on the heels of a rival drug from Teva, Austedo (deutetrabenazine) which gained FDA clearance for the treatment of chorea associated with Huntington’s disease ...

These findings complement recently announced patient-reported outcome data from the Phase 4 KINECT-PRO™ study of INGREZZA, which was the first of its kind to specifically measure and report ...

Ingrezza Sprinkle is available in the 3 dosage strengths: 40mg, 60mg, and 80mg. Ingrezza ® Sprinkle (valbenazine) is now available for the treatment of adults with tardive dyskinesia and chorea ...

Ingrezza (valbenazine) is a brand-name oral capsule prescribed for tardive dyskinesia and Huntington’s chorea. The cost of the drug with and without insurance can depend on several factors.

SAN DIEGO, July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today announced the launch of a new sprinkle formulation of INGREZZA ® (valbenazine) capsules ...

He emphasized the strong performance of INGREZZA, which is poised for double-digit year-over-year growth despite moderated expectations compared to 2024, the company’s highest growth year to date.

"Our clinical studies have shown clinically meaningful and sustained improvement in tardive dyskinesia with INGREZZA, and these remission data add to the body of evidence characterizing the robust ...